2019 ESC Guidelines On Diabetes, Pre-diabetes, And Cardiovascular Diseases Developed In Collaboration With The EASD.
F. Cosentino, P. Grant, V. Aboyans, C. J. Bailey, A. Ceriello, V. Delgado, M. Federici, G. Filippatos, D. E. Grobbee, T. Hansen, H. Huikuri, I. Johansson, P. Jüni, M. Lettino, N. Marx, L. Mellbin, C. J. Östgren, B. Rocca, M. Roffi, N. Sattar, P. Seferovic, M. Sousa-Uva, P. Valensi, D. Wheeler
Published 2019 · Medicine
Download PDFAnalyze on Scholarcy
Authors/Task Force Members: Francesco Cosentino* (ESC Chairperson) (Sweden), Peter J. Grant* (EASD Chairperson) (United Kingdom), Victor Aboyans (France), Clifford J. Bailey (United Kingdom), Antonio Ceriello (Italy), Victoria Delgado (Netherlands), Massimo Federici (Italy), Gerasimos Filippatos (Greece), Diederick E. Grobbee (Netherlands), Tina Birgitte Hansen (Denmark), Heikki V. Huikuri (Finland), Isabelle Johansson (Sweden), Peter Jüni (Canada), Maddalena Lettino (Italy), Nikolaus Marx (Germany), Linda G. Mellbin (Sweden), Carl J. € Ostgren (Sweden), Bianca Rocca (Italy), Marco Roffi (Switzerland), Naveed Sattar (United Kingdom), Petar M. Seferovi c (Serbia), Miguel Sousa-Uva (Portugal), Paul Valensi (France), David C. Wheeler (United Kingdom)
This paper references
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
K. Ray (2009)
Do men develop type 2 diabetes at lower body mass indices than women?
J. Logue (2011)
Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K
MR MacDonald (2010)
Dabigatranversuswarfarin in patients with atrial fibrillation
SJ Connolly (2009)
Torp-Pedersen C, Pehrson S; DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure
L Kober (2016)
food groups, and eating patterns in the management of diabetes: a systematic review of the literature
M L Wheeler (2010)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. Chapman (2011)
Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year followup of the SYNTAX trial
S J Head (2014)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
P. Kirchhof (2016)
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.
G. Stone (2016)
Effects of combination lipid therapy in type 2 diabetes mellitus.
H. Ginsberg (2010)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A. Keech (2005)
Diabetic cardiomyopathy: the search for a unifying hypothesis.
I. Poornima (2006)
Diabetes, glucose level, and risk of sudden cardiac death.
X. Jouven (2005)
Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia.
E. Cosson (2003)
2017 EACTS Guidelines on perioperative medication in adult cardiac surgery.
M. Sousa-Uva (2018)
Effect of carvedilol on survival in severe chronic heart failure.
M. Packer (2001)
Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study
M. Demant (2014)
Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study.
F. G. Fowkes (1992)
GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last.
J. Bassand (1994)
Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients.
J. Puskas (2012)
Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial.
S. Head (2014)
The Assessment of Endothelial Function: From Research Into Clinical Practice
A. Flammer (2012)
Diabetes and abdominal aortic aneurysms.
P. de Rango (2014)
Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study
J. Gerritsen (2000)
Home versus center based physical activity programs in older adults.
N. Ashworth (2005)
Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus.
R. Scognamiglio (2006)
Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators.
V. Dz̆avík (2001)
Cardiovascular Disease Mortality in Europeans in Relation to Fasting and 2-h Plasma Glucose Levels Within a Normoglycemic Range
F. Ning (2010)
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classification.
A. Bradbury (2010)
Reflex and Tonic Autonomic Markers for Risk Stratification in Patients With Type 2 Diabetes Surviving Acute Myocardial Infarction
P. Barthel (2011)
ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes
L. Bowman (2018)
Empowerment Program for People With Prediabetes: A Randomized Controlled Trial
M. Chen (2017)
Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes
E. Bosi (2013)
Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes.
M. Kamalesh (2013)
The effect of digoxin on mortality and morbidity in patients with heart failure.
G. Perry (1997)
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease
J. Tuomilehto (1994)
Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II)
L. Vanhees (2012)
Dowomen exhibit greater differences in established andnovel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study
SG Wannamethee (2012)
FolsomAR, SiscovickDS,RosamondWD.Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study
AM Kucharska-Newton (2010)
Flash glucosesensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial
T Haak (2017)
Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein.
F. Cosentino (2008)
Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group.
L. Amato (1997)
Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist
O. Vardeny (2014)
[ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012].
J. J. V. McMurray (2012)
Tools for predicting the risk of type 2 diabetes in daily practice.
P. Schwarz (2009)
Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial
Y. Hirakawa (2014)
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
A. Dasgupta (2009)
CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program
K W Mahaffey (2018)
Preventing microalbuminuria in type 2 diabetes.
M. Mauer (2005)
Abnormal glucose metabolism is associated with reduced left ventricular contractile reserve and exercise intolerance in patients with chronic heart failure.
M. Egstrup (2013)
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
B. Zinman (2014)
An evaluation of the effectiveness of self‐management interventions for people with type 2 diabetes after an acute coronary syndrome: a systematic review
Mu'ath Tanash (2017)
Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial
H. Arima (2014)
[2014 ESC Guidelines on the diagnosis and treatment of aortic diseases].
R. Erbel (2014)
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria
K. Borch-Johnsen (1999)
Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial
M. Morice (2014)
Simple non-invasive assessment of advanced glycation endproduct accumulation
R. Meerwaldt (2004)
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
G. Tocci (2011)
A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).
T. Takagi (2009)
Personalised care planning for adults with chronic or long-term health conditions.
A. Coulter (2015)
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
F. Ismail-Beigi (2010)
The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals.
C. Kastorini (2011)
Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.
Steven C. Halbert (2010)
Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial
L. Wallentin (2014)
Comparison of sirolimus-eluting stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 7-year follow-up of a randomized trial.
S. Blazek (2015)
Effectiveness of group‐based self‐management education for individuals with Type 2 diabetes: a systematic review with meta‐analyses and meta‐regression
K. Odgers-Jewell (2017)
Advanced glycation end‐products (AGEs) and heart failure: Pathophysiology and clinical implications
Jasper W.L. Hartog (2007)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
M. Bursztyn (2016)
Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach
G. Mancia (2017)
Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance
H. Chatterton (2012)
QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up
C. Stettler (2006)
Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators.
H. Barnett (1998)
Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy).
M. Maeng (2011)
Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
M. Gheorghiade (2013)
Trial of everolimus-eluting stents or bypass surgery for coronary disease.
S. Park (2015)
GenderSpecific short and long-term mortality in diabetic versus nondiabetic patients with incident acute myocardial infarction in the reperfusion era (the MONICA/KORA Myocardial Infarction Registry)
C Meisinger (2010)
CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes
B Neal (2017)
Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials
Y. Zhao (2010)
Basal insulin and cardiovascular and other outcomes in dysglycemia.
H. Gerstein (2012)
Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial
J. Zhou (2018)
Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
J. Ferreiro (2011)
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
M. Konstam (2009)
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Mikhail Kosiborod (2013)
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
L. Mauri (2014)
Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty
S. Singh (2014)
Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus
H. Lutgers (2009)
Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study
Jens Oellgaard (2018)
Correction: The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
D. V. Rados (2016)
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
A. Adler (2000)
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
C. Baigent (2002)
Fixed-dose combinations improve medication compliance: a meta-analysis.
S. Bangalore (2007)
Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
S. James (2010)
5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome.
P. Damman (2010)
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms
J. Kim (2006)
Development of life-expectancy tables for people with type 2 diabetes.
J. Leal (2009)
Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease.
E. Hannan (2014)
Early versus delayed, provisional eptifibatide in acute coronary syndromes.
R. Giugliano (2009)
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening
M. Lièvre (2011)
B. Frier (2005)
Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial
L. Mellbin (2008)
Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial.
G. Dangas (2014)
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI
Runjun Li (2017)
Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial.
A. Kapur (2010)
Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials
G. Thanassoulis (2014)
Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
M. Mazidi (2017)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
M. Nauck (2017)
Prognosis of patients with atherothrombotic disease: a prospective survey in a non-hospital setting.
J. Ferrières (2006)
Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions.
M. Engelgau (2004)
Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study
G. Assmann (2002)
Spironolactone in patients with heart failure.
G. Glick (2000)
Chronic Kidney Disease in Diabetes.
P. McFarlane (2018)
Dietary advice for treatment of type 2 diabetes mellitus in adults.
H. Moore (2004)
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials.
S. Saha (2010)
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
J. Eriksson (2016)
Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients
D. Ewing (2004)
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
G. Viberti (2002)
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
A. Go (2001)
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.
Deepak L. Bhatt (2002)
[2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death].
S. Priori (2015)
Smoking Cessation in Patients With Acute Coronary Syndrome.
C. Franck (2018)
Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients
K. Koskinas (2016)
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
M. R. Macdonald (2008)
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
N. Chaturvedi (2008)
Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials.
K. Radack (1991)
Effect of beta blockers on incidence of newcoronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease
WS Aronow (2001)
2.3 Management of lower extremity artery disease in diabetes
. . . . . . . . . . . . . . . . . . . . . Aortic
What predicts long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors.
A. Kilic (2012)
Pharmacologic management of patients with both heart failure and diabetes
Michael R. Macdonald (2009)
Stroke Council. Health literacy and cardiovascular disease: fundamental relevance to primary and secondary prevention: a scientific statement from the
Management of hyperglycaemia in type 54 ESC
S E Inzucchi
Doron Aronson; Italy: Italian Federation of Cardiology
[Glucagon-like peptide-1 receptor agonists].
Yamato Mashimo (2015)
The utility of ultrasonic tissue characterization of carotid plaque in the prediction of cardiovascular events in diabetic patients.
Y. Irie (2013)
Ranibizumab: in diabetic macular oedema. Drugs 2012;72:509–523
JE Frampton (2012)
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
R. Wing (2011)
Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial.
C. Jennings (2014)
[Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].
M. Ai (2010)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
C. Baigent (2011)
Thromboxane biosynthesis and platelet function in type II diabetes mellitus.
G. Daví (1990)
Discontinuation of Statins in Routine Care Settings
Huabing Zhang (2013)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.
B. Scirica (2015)
Nutrition Therapy Recommendations for the Management of Adults With Diabetes
A. Evert (2013)
Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.
C. Emdin (2015)
Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial
S. Griffin (2011)
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions
D. Nathan (2013)
The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction.
N. Cheung (2006)
Influence of blood glucose on heart rate and cardiac autonomic function. The DESIR study
P. Valensi (2011)
Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association
S. Colberg (2016)
Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe.
J. Lindström (2010)
The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.
M. Bartnik (2004)
Distribution and Correlates of Sonographically Detected Carotid Artery Disease in the Cardiovascular Health Study
D. O'leary (1992)
Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria
P. Gæde (2004)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
N. Sattar (2010)
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.
P. Serruys (2009)
Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells.
G. Zeng (1996)
No excess12-yearmortality inmen with impairedglucose tolerance who participated in the Malmo Preventive Trial with diet and exercise
KF Eriksson (1998)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
S Yusuf (2000)
Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
S P Marso (2016)
Prevalence of and risk factors associated with carotid artery stenosis: the Tromso Study
EB Mathiesen (2001)
20 220.127.116.11 Effects of lifestyle intervention and weight loss
. . . . . . . . . . . . Management
RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes
C P Cannon (2015)
Apixaban versus warfarin in patients with atrial fibrillation.
C. Granger (2011)
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
S. Schinner (2009)
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis
T. Palmerini (2012)
Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus
A. Hernández (2011)
Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study
G. Suarez (2005)
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani (2018)
Person-Centered Care — Ready for Prime Time
I. Ekman (2011)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker (2019)
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
K. Malmberg (2005)
Coronary Artery Bypass Surgery Improves Outcomes in Patients With Diabetes and Left Ventricular Dysfunction.
J. Nagendran (2018)
External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes
S. van Dieren (2010)
Performance of an A1C and Fasting Capillary Blood Glucose Test for Screening Newly Diagnosed Diabetes and Pre-Diabetes Defined by an Oral Glucose Tolerance Test in Qingdao, China
X. Zhou (2009)
Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.
J. Detry (1994)
Carotid Plaque Calcification Predicts Future Cardiovascular Events in Type 2 Diabetes
Saula Vigili de Kreutzenberg (2015)
Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach.
S. Hobbs (2003)
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology
C. Maack (2018)
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation
R. Hart (2000)
Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects.
F. Abbasi (2008)
Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients
C. Gazzaruso (2011)
Superiority of moderate control of hyperglycemia to tight control in patients undergoing coronary artery bypass grafting.
C. Bhamidipati (2011)
Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions
Rebecca Herbst (2017)
Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort
V. Ritsinger (2015)
Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the euro heart survey on diabetes and the heart.
M. Anselmino (2010)
Long-term effects of intensive glucose lowering on cardiovascular outcomes.
H. Gerstein (2011)
Comparison of diagnostic criteria to detect undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome
M. de Mulder (2011)
Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
B. Hemmingsen (2011)
The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock.
A. Kengne (2010)
Cardiac arrhythmias in hypoglycaemia.
S. Heller (2002)
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus
F. Santilli (2010)
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus.
L. Rijzewijk (2008)
Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions
William M. Schultz (2018)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
J. Rosenstock (2019)
Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial
M. Riddle (2010)
Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
R. Holman (2017)
Sudden cardiac death in diabetes
DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes
S P Marso (2017)
Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study.
Q. Gong (2019)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
A. Patel (2008)
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
Dean J. Kereiakes (2010)
[2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)].
M. Roffi (2016)
The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis
V. Perkovic (2008)
Antiplatelet and antithrombotic drugs (see section 6.5)
The safety of statins in clinical practice
J. Armitage (2007)
Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis
C. Gillies (2007)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Edmund J. Lewis (2001)
Everolimus Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Patients With Diabetes Mellitus and Multivessel Disease
S. Bangalore (2015)
U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction.
D. Pinto (2005)
10-year follow-up of intensive glucose control in type 2 diabetes.
R. Holman (2008)
Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial
E. Toledo (2013)
Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes.
K. Ramanathan (2017)
Are Individuals With Diabetes Seeing Better?
R. Klein (2010)
Shifting from glucose diagnostic criteria to the new HbA1c criteria would have a profound impact on prevalence of diabetes among a high‐risk Spanish population
B. Costa (2011)
A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack
P. Rothwell (2005)
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
J. Nielsen (2014)
New treatment guidelines for a patient with diabetes and hypertension.
C. Mogensen (2003)
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial.
H. Selker (2012)
Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial.
S. Blazek (2013)
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial
Y. Saito (2017)
Evidence for a Specific Diabetic Cardiomyopathy: An Observational Retrospective Echocardiographic Study in 656 Asymptomatic Type 2 Diabetic Patients
I. Pham (2015)
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
M. Flather (2000)
High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells: Role of Protein Kinase C and Reactive Oxygen Species
F. Cosentino (2003)
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis.
F. G. Fowkes (2008)
The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV
Bahira Shahim (2017)
Rivaroxaban in patients with a recent acute coronary syndrome.
J. Mega (2012)
Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin
V. Evangelista (2007)
Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk
Elaine Chow (2014)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
P. Home (2009)
The influence of autonomic neuropathy on mortality in insulin-dependent diabetes.
I. O'brien (1991)
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Min Jun (2010)
Apixaban in patients with atrial fibrillation.
S. Connolly (2011)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
M. Valgimigli (2018)
Follow-up report on the diagnosis of diabetes mellitus.
S. Genuth (2003)
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.
I. D. de Boer (2011)
Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials.
F. McAlister (2004)
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
S. Yusuf (2003)
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.
J. M. Lee (2009)
The association between glucose abnormalities and heart failure in the population-based Reykjavik study.
I. Thrainsdottir (2005)
Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial
RJ Sigal (2007)
Czech Republic: Czech Society of Cardiology, Ale s Linhart
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum
W. Cefalu (2017)
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
Caprie Steering Committee (1996)
Sabatine MS; DECLAREÀTIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes
S D Wiviott (2019)
Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes
W Duckworth (2009)
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
J. Fulcher (2015)
Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
D. Castagno (2011)
Clinical utility of the exercise ECG in patients with diabetes and chest pain.
D. Lee (2001)
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
A. Maggioni (2002)
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
J. McMurray (2003)
The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients
Joseph Dichiara (2007)
Guideline for management of postmeal glucose.
A. Ceriello (2008)
Hypoglycemia and Cardiovascular Risks
B. Frier (2011)
Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.
W. Mampuya (2013)
Diagnostic accuracy of the postexercise ankle–brachial index for detecting peripheral artery disease in suspected claudicants with and without diabetes
P. Tehan (2018)
Associations Between the Ankle-Brachial Index and Cardiovascular and All-Cause Mortality Are Similar in Individuals Without and With Type 2 Diabetes
N. M. Hanssen (2012)
A Metabolic Mechanism For Cardiac K+ Channel Remodelling
G. Rozanski (2002)
EHRA/HRS/APHRS expert consensus on ventricular arrhythmias.
Christian Torp Pedersen (2014)
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
Deepak L. Bhatt (2016)
Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.
MariaGrazia Franzosi (1998)
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
S. Nissen (2016)
Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels – overview and meta-analyses of randomized trials
C. Thomopoulos (2014)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
D. Fitchett (2016)
Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial.
J. Timmer (2007)
Contraindications can damage your health—is metformin a case in point?
A. Holstein (2005)
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
C. Daly (2005)
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study
P. Gæde (1999)
Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial
A. Jorsal (2017)
Does Nurse Case Management Improve Implementation of Guidelines for Cardiovascular Disease Risk Reduction?
K. Berra (2011)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
R. Turner (1998)
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.
Jens Oellgaard (2017)
Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Nutrition Intervention Evidence Reviews and Recommendations.
Janice MacLeod (2017)
Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
E. Vermes (2003)
Platelet activation and atherothrombosis.
G. Daví (2007)
Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
K. Malmberg (1997)
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials
B. Scally (2018)
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
A. K. Sjølie (2008)
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399–2405
P Massin (2010)
Brott TG; CREST Investigators. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial
B K Lal (2012)
Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes
S P Marso (2016)
Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group
O Vaccaro (2017)
Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study.
Jung Min Ahn (2015)
Effect of Bilateral Internal Mammary Artery Grafts on Long-Term Survival: A Meta-Analysis Approach
G. Yi (2014)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
S. Marso (2017)
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo F. Piepoli (2017)
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b
V. Aboyans (2018)
Putting evidence into practice: Smoking Cessation. Summer 2007,
K. Brunnhuber (2007)
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis.
K. McBrien (2012)
Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure
G. Mancia (2006)
Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials.
S. Jee (2001)
Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)
G. Mancia (2003)
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.
F. Turnbull (2005)
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).
R. Stevens (2001)
The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure.
S. Verma (2017)
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
H. Gerstein (2001)
Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet
F. Sacks (2001)
Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study
R. Guzder (2005)
Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review
R. Hinchliffe (2016)
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.
L. Køber (2016)
Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM
P. Tatti (1998)
Ten-Year Mortality and Cardiovascular Morbidity in the Finnish Diabetes Prevention Study—Secondary Analysis of the Randomized Trial
M. Uusitupa (2009)
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes Vytorin Efficacy International Trial)
R. Giugliano (2018)
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
R. Holman (2017)
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
B. Scirica (2013)
Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects
M. Taskinen (2011)
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.
J. McMurray (2018)
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry
M. Alberts (2009)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
M. Sabatine (2017)
Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double‐blind trial
M. Catalano (2007)
Patient-Centered Medicine: Transforming the Clinical Method
C. A. Johnson (1995)
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.
C. Patrono (2017)
Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes
P. Gæde (2008)
Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
G. Sarno (2012)
The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity.
J. Lindström (2003)
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.
R. D'Agostino (2001)
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
J. Chiasson (2003)
Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method.
E. Lerchbaum (2013)
The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease: Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction
B. Chaitman (2009)
Randomized Trial of Bilateral versus Single Internal-Thoracic-Artery Grafts.
D. Taggart (2016)
Strategies for multivessel revascularization in patients with diabetes.
M. Farkouh (2012)
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
A. Kastrati (2006)
Randomized controlled trial comparing impact on platelet reactivity of twice‐daily with once‐daily aspirin in people with Type 2 diabetes
M. Bethel (2016)
Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress.
G. Camici (2007)
Exertional Leg Pain in Patients With and Without Peripheral Arterial Disease
J. Wang (2005)
A Study on Efficacy of Empowerment Training among Diabetes Patients
Hsiangchi Wu (2011)
Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance
A. Mari (2009)
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
L. Hansson (2000)
Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events.
Kristen M Franklin (2004)
Global Diabetes Prevention Interventions: A Systematic Review and Network Meta-analysis of the Real-World Impact on Incidence, Weight, and Glucose
K. Galaviz (2018)
Hypoglycaemia and cognitive function. Diabetes Obes Metab 2005;7:493–503
RE Warren (2005)
1.2.1 Established oral glucose-lowering drugs
Reduction in ischemic 62 ESC
D L Bhatt
Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials
O. F. Clerc (2018)
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.
J. Brown (2003)
Standards of medical care in diabetes.
Aesha Drozdowski (2004)
Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions
Eleanor Barry (2017)
Krum H; VIVIDD Trial Committees and Investigators. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial
Jjv Mcmurray (2018)
Schaper NC; International Working Group on the Diabetic Foot. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review
R J Hinchliffe (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
S. Marso (2016)
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
J. McMurray (2014)
Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease.
E. Hannan (2008)
Sudden death, impaired glucose tolerance, and diabetes in Japanese American men.
J. Curb (1995)
Chapter V: Diabetic foot.
M. Lepäntalo (2011)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. Eikelboom (2017)
Current controversies in the use of haemoglobin A1c
M. Hare (2012)
Absence of Coronary Artery Calcium Identifies Asymptomatic Diabetic Individuals at Low Near-Term But Not Long-Term Risk of Mortality: A 15-Year Follow-Up Study of 9715 Patients
Valentina Valenti (2016)
High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes
L. B. Boonman-de Winter (2012)
Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy.
M. Zellweger (2014)
Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial
J. A. Black (2014)
Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus.
J. I. Mann (2004)
European Guidelines on Cardiovascular Disease Prevention
G. Boysen (2009)
Glucose control and vascular complications in veterans with type 2 diabetes.
W. Duckworth (2009)
Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies.
K. Malmberg (1989)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
The Control Group (2009)
Armenia: Armenian Cardiologists Association, Parounak H. Zelveian; Austria: Austrian Society of Cardiology
37 8.2 Mechanisms of left ventricular dysfunction in diabetes mellitus
Ulf Landmesser (Germany), Christophe Leclercq (France), Maddalena Lettino (Italy)
Esc Committee For Practice
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution)
Agency European Medicines
Bilateral versus Single Internal‐Thoracic‐Artery Grafts at 10 Years
D. Taggart (2019)
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
R. Altman (1994)
Achievement of goals in U.S. diabetes care, 1999-2010.
M. Ali (2013)
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
S. Zoungas (2014)
Liraglutide and Renal Outcomes in Type 2 Diabetes
J. Mann (2017)
Preventionof type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health 2009;9:342
Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
J Tuomilehto (2001)
Diabetes and cardiovascular disease.
J. Sowers (1999)
Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)
R. Wilcox (2007)
Comparative study of prognostic value for coronary disease risk between the U.K. prospective diabetes study and Framingham models.
I. Protopsaltis (2004)
Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists.
S. Levy (1999)
Transthoracic echocardiographic abnormalities in asymptomatic diabetic patients: association with microalbuminuria and silent coronary artery disease.
M. T. Nguyễn (2011)
Using the Framingham model to predict heart disease in the United Kingdom: retrospective study
S. Ramachandran (2000)
Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study
C. Roumen (2008)
[2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure].
P. Ponikowski (2016)
Age of Onset and Type of Diabetes
M. Laakso (1985)
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
L. Bellamy (2009)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
B. Zinman (2015)
Epidemiology of peripheral artery disease.
M. Criqui (2015)
Mortality and Vascular Morbidity in Older Adults With Asymptomatic Versus Symptomatic Peripheral Artery Disease
C. Diehm (2009)
Overcoming Clinical Inertia: A Randomized Clinical Trial of a Telehealth Remote Monitoring Intervention Using Paired Glucose Testing in Adults With Type 2 Diabetes
D. Greenwood (2015)
Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis.
E. Agardh (2011)
Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra‐Virgin Olive Oil or Nuts
R. Estruch (2018)
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study.
F. Wackers (2004)
Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus.
J. Boyer (2004)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
G. Filippatos (2016)
Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial
A. Ahmed (2006)
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Katherine J. Kearney (2017)
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
P. Sever (2005)
Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas.
R. Shorr (1997)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B. Brenner (2001)
Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis.
D. Umpierre (2011)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
P. Kirchhof (2016)
Increasing glucose levels and BMI predict future heart failure Experience from the Reykjavík Study
I. Thrainsdottir (2007)
Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?
Anselm K. Gitt (2012)
Bhatt DL; REACH Registry Investigators. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease
S Bangalore (2012)
Effect of a multifactorial intervention on mortality in type 2 diabetes.
P. Gaede (2008)
Inzucchi SE; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial
L H Young (2009)
EACTS Guidelines on perioperative medication in adult cardiac surgery
M Sousa-Uva (2017)
Yusuf S; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind
S J Connolly (2018)
Myocardial Steatosis and Biventricular Strain and Strain Rate Imaging in Patients With Type 2 Diabetes Mellitus
A. Ng (2010)
Clinical Utility of Carotid Ultrasonography in the Prediction of Cardiovascular Events in Patients with Diabetes: A Combined Analysis of Data Obtained in Five Longitudinal Studies
N. Katakami (2018)
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes
F. Zaccardi (2015)
Association Between Diffuse Myocardial Fibrosis by Cardiac Magnetic Resonance Contrast-Enhanced T1 Mapping and Subclinical Myocardial Dysfunction in Diabetic Patients: A Pilot Study
A. Ng (2012)
2018 ESC/ESH Guidelines for the management of arterial hypertension.
B. Williams (2018)
Effectiveness of individual strategies for the empowerment of patients with diabetes mellitus: A systematic review with meta-analysis.
Jéssica Azevedo Aquino (2018)
Impact of Subclinical Atherosclerosis on Cardiovascular Disease Events in IndividualsWithMetabolic Syndrome and Diabetes The Multi-Ethnic Study of Atherosclerosis
S. Malik (2011)
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
K. Ueki (2017)
Glycemic load, exercise, and monitoring blood glucose (GEM): A paradigm shift in the treatment of type 2 diabetes mellitus.
D. Cox (2016)
Does coronary Atherosclerosis Deserve to be Diagnosed earlY in Diabetic patients? The DADDY-D trial. Screening diabetic patients for unknown coronary disease.
F. Turrini (2015)
Unmeasured Confounders in Observational Studies Comparing Bilateral Versus Single Internal Thoracic Artery for Coronary Artery Bypass Grafting: A Meta‐Analysis
M. Gaudino (2018)
Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials
A. Jobs (2017)
Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: A case-control study.
F. Zaccardi (2017)
Association of Imaging Markers of Myocardial Fibrosis With Metabolic and Functional Disturbances in Early Diabetic Cardiomyopathy
C. Jellis (2011)
Exercise Training for Type 2 Diabetes Mellitus: Impact on Cardiovascular Risk A Scientific Statement From the American Heart Association
T. Marwick (2009)
The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT)
V. Kadirkamanathan (1998)
The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.
A. Krahn (1995)
Prevalence and characteristics of diabetic patients in a chronic heart failure population.
C. Kistorp (2005)
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
B. Pitt (2003)
The incidence of congestive heart failure in type 2 diabetes: an update.
G. Nichols (2004)
Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients.
E. Mills (2011)
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
W. Boden (2011)
Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.
E. Benjamin (1994)
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
K. Margulies (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
C. Wanner (2016)
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
X. Xie (2016)
Measurement of blood glucose: comparison between different types of specimens
B. Carstensen (2008)
Cardiovascular Determinants of Carotid Artery Disease: The Rotterdam Elderly Study
M. Bots (1992)
A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
D. Clément (1996)
Prediction of Mortality by Exercise Echocardiography: A Strategy for Combination With the Duke Treadmill Score
T. Marwick (2001)
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
S. Bangalore (2012)
Altered Mitochondrial Dynamics Contributes to Endothelial Dysfunction in Diabetes Mellitus
S. Shenouda (2011)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
A. Hernandez (2018)
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
M. Miller (2011)
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.
A. Camm (2012)
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
R. L. Frye (2009)
Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: Results from the DIAD study
S. Tandon (2012)
Characteristics and Prognosis in Women and Men With Type 1 Diabetes Undergoing Coronary Angiography: A Nationwide Registry Report
V. Ritsinger (2018)
Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography the Silent Diabetes Study
R. Doerr (2011)
Usefulness of carotid plaque (sum and maximum of plaque thickness) in combination with intima‐media thickness for the detection of coronary artery disease in asymptomatic patients with diabetes
S. Akazawa (2016)
Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis
D. Giacoppo (2017)
Reappraisal of Europeanguidelines on hypertension management: a EuropeanSociety of Hypertension
G Mancia (2009)
Egypt: Egyptian Society of Cardiology, Hosam Hasan-Ali; Estonia: Estonian Society of Cardiology
Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
B Pitt (1999)
NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial
K B Margulies (2016)
Use of Ggycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
L. Wallentin (2009)
The impactof gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus
TJ Orchard (1996)
Effect of valsartan on the incidence of diabetes and cardiovascular events.
J. McMurray (2010)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Declare–Timi Investigators (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
H. Gerstein (2019)
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
B. Pitt (2000)
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
R. Pisters (2010)
Effects of torcetrapib in patients at high risk for coronary events.
P. Barter (2007)
Prospective Study of Sudden Cardiac Death Among Women in the United States
C. Albert (2003)
Comment on: Hanssen et al. Associations Between the Ankle-Brachial Index and Cardiovascular and All-Cause Mortality Are Similar in Individuals Without and With Type 2 Diabetes: Nineteen-Year Follow-Up of a Population-Based Cohort Study. Diabetes Care 2012;35:1731–1735
I. Tasci (2013)
A 14‐year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy
A. Forsén (2004)
Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
M. Taskinen (2010)
Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial
M. Komajda (2015)
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
B. Pitt (1999)
Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline.
J. Rosenzweig (2008)
Incidence of and risk factors for atrial fibrillation in older adults.
B. Psaty (1997)
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes
J. Östergren (2008)
Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
G. Fragasso (2003)
Exercise Prescription in Patients with Different Combinations of Cardiovascular Disease Risk Factors: A Consensus Statement from the EXPERT Working Group
D. Hansen (2018)
Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up
F. Cavalot (2011)
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial
K. Dickstein (2002)
The diabetes risk score: a practical tool to predict type 2 diabetes risk.
J. Lindström (2003)
Coffee consumption and risk of total and cardiovascular mortality among patients with type 2 diabetes
S. Bidel (2006)
Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects.
S. Bernard (2005)
The association of heart failure with insulin resistance and the development of type 2 diabetes.
J. Kostis (2005)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
V. Vallon (2016)
Contemporary model for cardiovascular risk prediction in people with type 2 diabetes
A. Kengne (2011)
Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.
P. Shekelle (2003)
Sudden death due to cardiac arrhythmias.
H. Huikuri (2001)
Balancing the benefits of statins versus a new risk—diabetes
C. Cannon (2010)
Mechanisms of hypertension in the cardiometabolic syndrome
Josep Redon (2009)
Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction
A. Pavlović (2019)
Antiplatelet Therapy and Proton Pump Inhibition: Clinician Update
G. Moukarbel (2012)
Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes.
C. Lin (2012)
Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development
T. Hwang (2017)
Letter by Wang and Xu Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
J. Wang (2019)
Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly
L Amato (1997)
Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.
G. Li (2014)
The Influence of Glycemic Control on the Prognosis of Japanese Patients Undergoing Percutaneous Transluminal Angioplasty for Critical Limb Ischemia
M. Takahara (2010)
Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study.
R. D'Agostino (1994)
The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003;26:1895–1901
RE Maser (1901)
40 9.2.1 Ventricular premature beats and paroxysmal ventricular tachycardia
. . . . . Ventricular
Zeiher AM; Odyssey Outcomes Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome
G G Schwartz (2018)
Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology.
V. Gyberg (2015)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
I. Stratton (2000)
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.
K. Malmberg (1995)
Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events.
A. Svensson (2005)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
P. Kirchhof (2016)
Insulin signalling and the regulation of glucose and lipid metabolism
A. Saltiel (2001)
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
M. Abe (2011)
Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study.
D. Liao (2002)
Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers.
M. Bobbio (2003)
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
H. Ogawa (2008)
Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients: The DAI Study
C. Giorda (2007)
Recommendations for the evaluation of left ventricular diastolic function by echocardiography.
S. Nagueh (2009)
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
K. Kotseva (2009)
Long-Term Outcomes of Diabetic Patients With Critical Limb Ischemia Followed in a Tertiary Referral Diabetic Foot Clinic
L. Uccioli (2010)
Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes
O. Snorgaard (2017)
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
C. Johnston (2014)
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
J. Gaziano (2018)
PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.
M. Hülsmann (2013)
ESC / EACTS Guidelines on Myocardial Revascularisation
S. Achenbach (2012)
Reframing the association and significance of co‐morbidities in heart failure
F. Triposkiadis (2016)
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans‐Henrik Parving (2012)
Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes.
A. Tenerz (2003)
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
P. Deedwania (2005)
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
J. Berger (2006)
Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study.
E. Faglia (2005)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. Turnbull (2009)
The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects.
V. Aboyans (2008)
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
J. Belch (2008)
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
W. Knowler (2009)
Associations Between the Ankle- Brachial Index and Cardiovascular and All-CauseMortality Are Similar in IndividualsWithout andWith Type 2 Diabetes Nineteen-year follow-up of a population-based cohort study
The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
D. Bonds (2010)
The longterm effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study
G Li (2008)
[The Framingham function overestimates stroke risk for diabetes and metabolic syndrome among Spanish population].
B. Costa (2005)
Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.
S. Haas (2003)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
M. Pfeffer (2015)
Metabolic Syndrome, Insulin Resistance, and Roles of Inflammation – Mechanisms and Therapeutic Targets
G. Romeo (2012)
Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
O. Phung (2013)
Lipid‐altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials
Lawrence A Leiter (2011)
Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
N. Valentine (2012)
Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association.
V. Aboyans (2012)
Glycemic Thresholds for Diabetes-Specific Retinopathy
S. Colagiuri (2010)
Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials
C. Thomopoulos (2017)
Cost-Effectiveness of Percutaneous Coronary Intervention With Drug Eluting Stents Versus Bypass Surgery for Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: Results From the FREEDOM Trial
Elizabeth A. Magnuson (2013)
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
C. Investigators (2019)
Cardiovascular risk assessment scores for people with diabetes: a systematic review
P. Chamnan (2009)
Multimodality imaging in diabetic heart disease.
A. Ng (2011)
Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study).
J. Singh (2000)
Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study
M. Packer (2002)
Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial
M. Sabaté (2005)
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
W. Herrington (2018)
Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis.
A. S. Brown (1997)
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
K. Swedberg (2010)
Statins and congenital malformations: cohort study
B. Bateman (2015)
Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
S. L. Kristensen (2017)
Has the difference in mortality between percutaneous coronary intervention and coronary artery bypass grafting in people with heart disease and diabetes changed over the years? A systematic review and meta-regression
P. Herbison (2015)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaborati (2010)
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
P. Whelton (2005)
Inflammation and thrombosis in diabetes.
K. Hess (2011)
Inadequate Blood Glucose Control Is Associated With In-Hospital Mortality and Morbidity in Diabetic and Nondiabetic Patients Undergoing Cardiac Surgery
R. Ascione (2008)
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
L. Lindholm (2002)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
D. Nathan (2005)
Effect of guided self-determination youth intervention integrated into outpatient visits versus treatment as usual on glycemic control and life skills: a randomized clinical trial in adolescents with type 1 diabetes
G. R. Husted (2014)
The effect on serum cholesterol levels of coffee brewed by filtering or boiling.
A. Bak (1989)
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
Peter A. Gaede (2003)
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
R. Collins (2003)
Estimates of global mortality attributable to smoking in 2000
M. Ezzati (2003)
High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population
T. Saaristo (2008)
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure
M. Packer (2017)
Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia
I. Raz (2011)
Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
Jean-Guillaume Dillinger (2012)
Incremental prognostic value of stress myocardial perfusion imaging in asymptomatic diabetic patients.
W. Acampa (2013)
Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome
K. Ayers (2012)
Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association
F. Sacks (2017)
Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.
I. D. de Boer (2016)
[Variability in the calculation of coronary risk in type-2 diabetes mellitus].
J. Jimeno Mollet (2005)
Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
J. Borer (2010)
Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
R. Pop-Busui (2010)
Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study
B. Balkau (2004)
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus
D. Nathan (1993)
High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells.
F. Cosentino (1997)
Abdominal aortic aneurysms and diabetes mellitus.
K. Pafili (2015)
Two prospective studies found that elevated 2-hr glucose predicted male mortality independent of fasting glucose and HbA1c.
Q. Qiao (2004)
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study
A. Norhammar (2002)
Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients.
C. Locker (2004)
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Forceon Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World HeartFederation; International Atherosclerosis Society; and International Asso
G. AlbertiK (2010)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Odyssey Outcomes Investigators (2018)
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
L. Mellbin (2008)
Nutrition Recommendations and Interventions for Diabetes
MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
J. Knuuti (2019)
US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States.
Treatment potential for cholesterol management in patients with coronary heart disease in15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis
K Kotseva (2008)
Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery
O. Aziz (2007)
Ong TK; BEST Trial Investigators. Trial of everolimuseluting stents or bypass surgery for coronary disease
S J Park (2015)
Taggart DP; RADIAL Investigators. Radialartery or saphenous-vein grafts in coronary-artery bypass surgery
M Gaudino (2018)
Buse JB; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes
Jfe Mann (2017)
Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease
P W Serruys (2009)
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
J. Hall (2015)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
UK Prospective Diabetes Study Group (1998)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Odyssey Outcomes Investigators (2019)
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
C. Stettler (2008)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
J. Dormandy (2005)
Cardiovascular Risk Prediction Is Improved by Adding Asymptomatic Coronary Status to Routine Risk Assessment in Type 2 Diabetic Patients
E. Cosson (2011)
Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?
A. Ceriello (2009)
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications
S. Hernández-Díaz (2006)
Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study.
P. Valensi (2005)
Bilateral internal thoracic artery harvest and deep sternal wound infection in diabetic patients.
Salil V. Deo (2013)
Beta-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease
E. V. Simon (2013)
ESC/EAS Guidelines for the management of dyslipidaemias
Ž. Reiner (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
M. Sabatine (2017)
Glycaemic variability in diabetes: clinical and therapeutic implications.
A. Ceriello (2019)
Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis.
H. Thiele (2009)
Cardiovascular events during differing hypertension therapies in patients with diabetes.
M. Weber (2010)
Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients.
A. Norhammar (1999)
HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study
R. Borg (2010)
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.
B. Rocca (2018)
Impact of diabetes on carotid artery revascularization.
M. Hussain (2016)
Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta‐analysis
F. Zaccardi (2015)
Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.
T. Berg (1999)
Effect of systemic medications on onset and progression of diabetic retinopathy
P. Silva (2010)
Association of glucose metabolism with diastolic function along the diabetic continuum
R. Stahrenberg (2010)
Platelet activation in type 2 diabetes mellitus
P. Ferroni (2004)
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.
C. Stettler (2006)
An analysis of barriers to entry of cardiac rehabilitation in patients with diabetes: Using data from the National Audit of Cardiac Rehabilitation
A. Harrison (2018)
Risk of Cardiovascular Disease and Death in Individuals With Prediabetes Defined by Different Criteria: The Whitehall II Study
D. Vistisen (2018)
The role of patient education in the prevention and management of type 2 diabetes: an overview
A. Coppola (2015)
Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis.
M. Kavousi (2016)
The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study.
Aaron M. From (2010)
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
G. Montalescot (2013)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
B. Mihaylova (2012)
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
A. Scheen (2013)
Evolution of Percutaneous Coronary Intervention in Patients with Diabetes
J. Rana (2010)
The team approach to diabetes management: partnering with patients
P. Aschner (2007)
Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome
M. Adiels (2008)
Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease
E. Erdmann (2007)
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
J. Tuomilehto (2001)
Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection.
R. Kloner (2008)
Health Literacy and Cardiovascular Disease: Fundamental Relevance to Primary and Secondary Prevention: A Scientific Statement From the American Heart Association.
J. Magnani (2018)
Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
V. Charlton-Menys (2009)
The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes.
R. Klein (2009)
Antiplatelet agents for the treatment and prevention of atherothrombosis.
C. Patrono (2011)
High-sensitive troponin T is associated with all-cause and cardiovascular mortality in stable outpatients with type 2 diabetes (ZODIAC-37).
S. H. Hendriks (2016)
Prediction of mortality using measures of cardiacautonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008;31:556–561
D Ziegler (2008)
D’AgostinoRBSr., WilsonPW.Fasting andpostchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845–1850
JB Meigs (2002)
Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes
S D Wiviott (2007)
Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
L Mauri (2014)
2.1 Percutaneous coronary intervention vs. coronary artery bypass graft surgery
Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial
R. McManus (2018)
Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a crosssectional study
W Dinh (2010)
Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
Julie Galsgaard (2017)
Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension.
Macronutrients, Food Groups, and Eating Patterns in the Management of Diabetes
M. Wheeler (2012)
Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study
M. Pencina (2009)
Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies
R. Huxley (2005)
Risk Factors, Outcome, and Treatment in Subtypes of Ischemic Stroke: The German Stroke Data Bank
A. Grau (2001)
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
N. Sattar (2016)
[Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes].
J. Bassand (2008)
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
S. Connolly (2018)
Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta‐analysis
C. Fitzpatrick (2018)
Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials
C. Lamanna (2011)
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
L. Bowman (2018)
Zimmet P; Residual Risk Reduction Initiative. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
J C Fruchart (2008)
Diabetes and risk of stroke in atrial fibrillation
Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates.
F. Sacks (2009)
Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post‐Hoc Analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) Trial
M. Dauriz (2017)
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
W. White (2013)
Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
Nisa M. Maruthur (2016)
Diabetic retinopathy. Diabetes Care 2003;26:226–229
DS Fong (2003)
Kappetein AP; EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease
G W Stone (2016)
Diabetes, left ventricular systolic dysfunction, and chronic heart failure.
M. R. Macdonald (2008)
Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.
J. He (2001)
Diagnosis and Classification of Diabetes Mellitus
P. O S I T I O N S T A T E M E N T (2010)
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
D. Giugliano (1997)
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
C. Granger (2003)
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
D. Preiss (2011)
Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data
M. Lorenz (2012)
Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34 000 Patients
D. Eurich (2013)
Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease.
R. Cavalcante (2016)
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
G. Moneta (2010)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt (2019)
Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.
M. Franz (2015)
Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial
D. Wood (2008)
Effects of Different Modes of Exercise Training on Glucose Control and Risk Factors for Complications in Type 2 Diabetic Patients: a Meta-Analysis
N. Snowling (2007)
Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature.
P. Valensi (2011)
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
H. Abuissa (2005)
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.
C. Cannon (2006)
Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes.
A. Scheen (2013)
Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study
W. Dinh (2010)
Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintigraphy?
E. Cosson (2004)
Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data
S. Bain (2017)
Physical activity consultation for people with Type 2 diabetes. Evidence and guidelines
A. Kirk (2007)
A European evidence-based guideline for the prevention of type 2 diabetes.
B. Paulweber (2010)
Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study
J. Pallisgaard (2016)
The Effectiveness of Lifestyle Adaptation for the Prevention of Prediabetes in Adults: A Systematic Review
George Kerrison (2017)
Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry
O. Chioncel (2017)
Diabetes and idiopathic cardiomyopathy: a nationwide case-control study.
A. Bertoni (2003)
Peripheral arterial disease - epidemiological aspects
M. Criqui (2001)
Long-term use of ticagrelor in patients with prior myocardial infarction.
Marc P. Bonaca (2015)
Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data
S. Head (2018)
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
P. Rothwell (2018)
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.
M. Lean (2019)
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
E. Erdmann (2007)
Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction.
Suzanne V Arnold (2014)
Mean Platelet Volume, Platelet Distribution Width, and Platelet Count in Type 2 Diabetes Mellitus, Impaired Fasting Glucose, and Metabolic Syndrome: systematic review and meta-analysis
F. Zaccardi (2014)
EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION ( DASH ) DIET
Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials.
S. Nicholls (2008)
Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk prediction in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study
Anna H. Price (2017)
Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial
R. K. Simmons (2012)
Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus
G. Reboldi (2009)
Long-term results following operation for diabetic foot problems: arterial disease confers a poor prognosis.
W. Campbell (2000)
Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers
T. Tsujimoto (2017)
Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
M. Herz (2011)
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial
J. Beulens (2009)
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.
A. Folsom (2006)
Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
A. Adler (2003)
Effects of intensive glucose lowering in type 2 diabetes.
H. Gerstein (2008)
The natural history of diabetic autonomic neuropathy.
D. Ewing (1980)
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study
R. Schnabel (2009)
Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis.
C. Willi (2007)
QT interval, cardiovascular risk factors and risk of death in diabetes
M. Veglio (2004)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
S. Wiviott (2007)
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
G. Schwartz (2012)
Bain SC; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
B Zinman (2015)
EMPA-REG OUTCOME V R trial investigacardiovascular risk: results of the EMPA-REG OUTCOME V R trial
D Fitchett (2016)
Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.
M. Hughes (2008)
RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
P D Home (2009)
Oral glucose tolerance test and HbA 1 c for diagnosis of diabetes in patients undergoing coronary angiography: [corrected] the Silent Diabetes Study
R Doerr (2011)
Impact of Completeness of Revascularization on Long-Term Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)
L. Schwartz (2012)
Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies
A. Wood (2018)
Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial
Origin Trial Investigators (2014)
Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial.
T. Church (2010)
Predictors of diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes.
Jelena P. Seferović Mitrović (2012)
Glucometrics in Patients Hospitalized With Acute Myocardial Infarction: Defining the Optimal Outcomes-Based Measure of Risk
M. Kosiborod (2008)
Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes.
Z. Meiszterics (2017)
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
M. Pfeffer (2003)
[2016 European Guidelines on cardiovascular disease prevention in clinical practice].
M. Piepoli (2016)
Impact of hypoglycaemia on coronary artery disease and hypertension.
M. Fisher (2002)
Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial
A. Sandbæk (2014)
The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study)
N. Laiteerapong (2018)
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
M. Pfeffer (2003)
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
M. Cavender (2015)
Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions
A. Chait (2017)
Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC
J. Lachin (2014)
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
M. Lean (2018)
Obesity and diabetes in the developing world--a growing challenge.
Parvez Hossain (2007)
Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
D. Wald (2009)
Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications
E. Fabbrini (2010)
Bayesian Methods Affirm the Use of Percutaneous Coronary Intervention to Improve Survival in Patients With Unprotected Left Main Coronary Artery Disease
J. A. Bittl (2013)
Lifestyle factors and mortality among adults with diabetes: findings from the European Prospective Investigation into Cancer and Nutrition–Potsdam study *
U. Noethlings (2010)
Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study.
J. Gottdiener (2000)
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
S. Connolly (2006)
Long-term follow-up after tight control of blood pressure in type 2 diabetes.
R. Holman (2008)
Statin use during pregnancy: a systematic review and meta-analysis
D. M. Kusters (2012)
Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.
M. Zeller (2010)
Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
J. Crandall (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
O. Vaccaro (2017)
Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry
M. Dauriz (2017)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
J. Rosenstock (2019)
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part II
T. Lüscher (2003)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaborato (2012)
Benefits of Cardiac Rehabilitation on Cardiovascular Outcomes in Patients With Diabetes Mellitus After Percutaneous Coronary Intervention
M. Jiménez-Navarro (2017)
Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial
I. Raz (2009)
The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study.
J. Liu (2001)
Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study
Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association
American Heart Association Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease
J W Magnani
Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus.
A. Ng (2009)
Patient-centred medicine: Transforming the clinical method
J. Brown (1995)
C-reactive protein, fibrinogen, and cardiovascular disease prediction.
S. Kaptoge (2012)
EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION
P. R. R. Ecurrent (2001)
[Coronary risk estimation in Spain using a calibrated Framingham function].
J. Marrugat (2003)
Telmisartan, ramipril, or both in patients at high risk for vascular events.
S. Yusuf (2008)
Action to Control Cardiovascular Risk in Diabetes
M. Özkaya (2013)
Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study
Q. Gong (2010)
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
L. Rydén (2000)
NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus.
M. Hülsmann (2008)
Risk of All‐Cause Mortality in Diabetic Patients Taking &bgr;‐Blockers
T. Tsujimoto (2018)
Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial.
A. Kappetein (2013)
Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery.
J. Kapoor (2008)
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. Inzucchi (2012)
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial
B. Neal (2017)
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
N. Marx (2016)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
A. Patel (2007)
Impact of diabetes mellitus on the treatment effect of percutaneous or surgical revascularization for patients with unprotected left main coronary artery disease: a subgroup analysis of the MAIN-COMPARE study.
Won-Jang Kim (2009)
Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction.
M. Kosiborod (2009)
Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory?
J. Stephens (2004)
Heart failure prevalence, incidence, and mortality in the elderly with diabetes.
A. Bertoni (2004)
Gender difference in the impact of type 2 diabetes on coronary heart disease risk.
A. Juutilainen (2004)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
S. Marso (2016)
Interventions for providers to promote a patient-centred approach in clinical consultations.
F. Dwamena (2012)
Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy.
D. V. Anand (2006)
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
A. Carr (2005)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
W. Knowler (2002)
Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors.
G. Nichols (2001)
In‐hospital and 1‐year mortality associated with diabetes in patients with acute heart failure: results from the ESC‐HFA Heart Failure Long‐Term Registry
G. Targher (2017)
COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment.
F. Pulcinelli (2009)
The Global Burden of Disease Study
C. Murray (2003)
Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology
V. Gyberg (2015)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Ž. Reiner (2011)
ESC Guidelines on the Diagnosis and Treatment of Peripheral Artery Diseases
M. Tendera (2012)
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Darren K Mcguire (2019)
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.
L. Mellbin (2013)
Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome.
M. Mack (2011)
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
George Sokos (2006)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker (2019)
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.
M. Coutinho (1999)
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
R. Turner (1998)
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
S. Salpeter (2003)
Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart
M. Anselmino (2008)
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
P. Kearney (2008)
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
R. Bilous (2009)
Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies
L WG J J X HC D AJ MH DR DA SAE H P R R RR JR M S N Gnatiuc Herrington Halsey Tuomilehto Fang Kim De B (2018)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C. Baigent (2005)
What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies
S. Tierney (2011)
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
UK Prospective Diabetes Study Group (1998)
Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care 2010;33:2692–6
SR Colberg (2010)
ESC Guidelines 3087b by gest on Jauary 27, 2015 D ow nladed fom
B Rocca (2012)
Iceland: Icelandic Society of Cardiology
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
The Emerging Risk Factors Collaboration (2010)
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a metaanalysis
F G Fowkes (2008)
Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study.
J. Lamparter (2014)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
A. Fournier (1994)
One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial).
H. Selker (2014)
Web-based collaborative care for type 1 diabetes: a pilot randomized trial.
K. Mccarrier (2009)
Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus—An Observational Study from the Swedish National Diabetes Register
B. Eliasson (2011)
Comparative effectiveness of revascularization strategies.
M. Habibi (2012)
The Association of Hemoglobin A1c With Incident Heart Failure Among People Without Diabetes: The Atherosclerosis Risk in Communities Study
K. Matsushita (2010)
Long-term efficacy and safety of carotid artery stenting versus endarterectomy: A meta-analysis of randomized controlled trials
Y. Li (2017)
Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function
I. Johansson (2018)
Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial
H. Gerstein (2013)
Diabetes as a risk factor for sudden death
B. Balkau (1999)
A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients.
E. Cosson (2010)
Influence of Diabetes on Long-Term Coronary Artery Bypass Graft Patency.
Sajjad Raza (2017)
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
P. Seferovic (2018)
Pericardial fat volume measured by non-contrast tomography improves risk prediction of subclinical coronary artery disease estimated by coronary artery calcium score and Framinghan risk score
L. Carvalho (2013)
Alcohol consumption and risk of type 2 diabetes in European men and women: influence of beverage type and body sizeThe EPIC–InterAct study
J. W. J. Beulens (2012)
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.
A. Thanopoulou (2010)
The global epidemiology of heart failure.
J. Young (2004)
Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview
S. Capes (2000)
Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
V. Ritsinger (2014)
Silent coronary artery disease and incidence of cardiovascular and mortality events at different levels of glucose regulation; results of greater than a decade follow-up.
F. Hadaegh (2015)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
S. Pearson (2011)
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.
T. Ninomiya (2009)
Fracture Risk After Initiation of Use of Canagliflozin
M. Fralick (2019)
The prognostic value of impaired walking distance on long-term outcome in patients with known or suspected peripheral arterial disease.
Inge I de Liefde (2009)
The Task Force on Myocardial Revascularisation of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on myocardial revascularization
W Wijns (2010)
1.1.2 ACCORD, ADVANCE, and
. . . . . . . . . . . . . . . . . . Control
Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
L SjöStröM (2004)
Physical Activity and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis.
D. Sluik (2012)
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
T. Davis (2010)
Sudden cardiac death after myocardial infarction in patients with type 2 diabetes.
M. Junttila (2010)
World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate and hyperglycaemia
Fourier Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease
M S Sabatine (2017)
PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction
M P Bonaca (2015)
Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial.
A. Abdul-Rahim (2016)
Ezetimibe added to statin therapy after acute coronary syndromes
Improve-It Investigators (2015)
Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients.
A. Gottsäter (1993)
Moving to an A1C-Based Diagnosis of Diabetes Has a Different Impact on Prevalence in Different Ethnic Groups
D. L. Christensen (2009)
Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis.
H. D. den Ruijter (2012)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
S. D. Wiviott (2008)
Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.
J. Muhlestein (2014)
Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
C. Cannon (2008)
The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
P. Cleary (2006)
Intake of fruit, vegetables, and antioxidants and risk of type 2 diabetes: systematic review and meta-analysis
M. Hamer (2007)
Radial‐Artery or Saphenous‐Vein Grafts in Coronary‐Artery Bypass Surgery
M. Gaudino (2018)
Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction
I. Gustafsson (1999)
Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension–2
L. Lindholm (2000)
Faculty of 1000 evaluation for Primary prevention of cardiovascular disease with a Mediterranean diet.
M. Fogelholm (2013)
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.
E. Erdmann (2001)
International Consensus on Use of Continuous Glucose Monitoring
T. Danne (2017)
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
S. Kahn (2003)
CHART: congestive cardiac failure in hospitals, an Australian review of treatment.
J. Wlodarczyk (2003)
Long-term Effects of Lifestyle Intervention or Metformin on Diabetes Development and Microvascular Complications: the DPP Outcomes Study
D. Nathan (2015)
Excess Mortality among Persons with Type 2 Diabetes.
T. Byers (2016)
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)
S. L. Kristensen (2017)
Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force
E. Balk (2015)
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
J. Seferovic (2017)
Randomized Trials of Nursing Interventions for Secondary Prevention in Patients With Coronary Artery Disease and Heart Failure: Systematic Review
J. Allen (2010)
Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus.
D. Aguilar (2010)
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
M. Bristow (2004)
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
C. Bailey (2019)
Impaired awareness of hypoglycaemia: a review.
A. Graveling (2010)
European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions
M. Crespo-Leiro (2016)
Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure
Erdmann Erland (2001)
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
X. Pi-Sunyer (2007)
Systematic review on the cost-effectiveness of self-management education programme for type 2 diabetes mellitus.
J. X. Lian (2017)
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
W. Cushman (2010)
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
D. Eurich (2007)
Definition, diagnosis and classificationof diabetes mellitus and its complications
WHO Consultation (1999)
Risk of development of diabetes mellitus after diagnosis of gestationaldiabetes.CMAJ : Canadian MedicalAssociation journal1⁄4Journal de l’Association Medicale Canadienne 2008;179:229–234
DS Feig (2008)
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.
P. Saenger (1993)
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.
R. Wing (2010)
Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study.
L. Moyé (1994)
Effects of medical therapies on retinopathy progression in type 2 diabetes.
E. Chew (2010)
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
K. Swedberg (2012)
Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study
S. Ikramuddin (2018)
An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials.
M. O'Donoghue (2012)
ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology
U. Sechtem (2013)
Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials
C. Thomopoulos (2016)
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
Kenneth W. Mahaffey (2018)
EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION
B. Pitt (2003)
Diabetic patients and beta-blockers after acute myocardial infarction.
J. Kjekshus (1990)
Effect of Aging on A1C Levels in Individuals Without Diabetes
L. Pani (2008)
Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites.
W. Aronow (1999)
Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study.
E. Barrett-connor (1991)
Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.
L. Niskanen (2001)
Patient adherence to medical treatment: a review of reviews
S. van Dulmen (2007)
Insulin resistance and risk of congestive heart failure.
E. Ingelsson (2005)
Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure.
S. Smooke (2005)
Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study.
E. Schroeder (2005)
Effectiveness of Percutaneous Coronary Intervention With Drug‐Eluting Stents Compared With Bypass Surgery in Diabetics With Multivessel Coronary Disease: Comprehensive Systematic Review and Meta‐analysis of Randomized Clinical Data
A. Hakeem (2013)
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.
L. Sjöström (2004)
Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial.
T. Saito (2011)
Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy
S. Sorrentino (2010)
Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.
P. Seferovic (2015)
Effect of ramipril on the incidence of diabetes.
J. Bosch (2006)
Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy.
E. Velazquez (2016)
The Health Effects of Passive Smoking: An Overview of Systematic Reviews Based on Observational Epidemiological Evidence
Shiyi Cao (2015)
Everolimus-eluting stents or bypass surgery for multivessel coronary disease.
S. Bangalore (2015)
Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease
R. Roussel (2015)
Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction.
M. Bartnik (2004)
HbA1c in diagnosing and predicting Type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study
P. Pajunen (2011)
Diabetes and the Accompanying Hyperglycemia Impairs Cardiomyocyte Calcium Cycling through Increased Nuclear O-GlcNAcylation*
R. Clark (2003)
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
S. James (2010)
Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study
A. Abbasi (2012)
Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: The GERODIAB observational cohort.
J. Doucet (2018)
The impact of revascularization on mortality in patients with nonacute coronary artery disease.
A. Jeremias (2009)
Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI).
E. Alderman (2004)
Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study
Araz Rawshani (2018)
Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart
M. Bartnik (2006)
Intensive walking exercise for lower extremity peripheral arterial disease: A systematic review and meta‐analysis
X. Lyu (2016)
Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes
C. Hage (2013)
Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus
L. Bowman (2018)
New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study.
F. Ledru (2001)
ON OXIDATIVE STRESS AND DIABETIC COMPLICATIONS
Vinod. Patel (2013)
Eplerenone in patients with systolic heart failure and mild symptoms.
F. Zannad (2011)
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
S. Laing (2003)
Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group.
I. Gustafsson (1999)
Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia
L. Opie (2008)
Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial
Lawrence A Leiter (2017)
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
T. Pieber (2017)
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
J. Fruchart (2008)
Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies.
A. H. Momsen (2009)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
H. Gerstein (2006)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial
HM Colhoun (2004)
Lipidmodifying therapies and risk of pancreatitis: a meta-analysis
D Preiss (2012)
GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial
S E Nissen (2016)
UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine
V. Kothari (2002)
38 8.4.1 Renin-angiotensin-aldosterone system and a neprilysin inhibitors
. . . . . . . . . . . . Mellitus
Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
B M Scirica (2013)
Kyrgyzstan: Kyrgyz Society of Cardiology, Saamai Abilova; Latvia: Latvian Society of Cardiology
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients 66 ESC
J P Seferovic
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
M. G. Wong (2016)
Clinical Implications of Echocardiographic Phenotypes of Patients With Diabetes Mellitus.
L. Ernande (2017)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
S. Nissen (2007)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
M. Jardine (2017)
Downregulation of Adipose Tissue Fatty Acid Trafficking in Obesity: A Driver for Ectopic Fat Deposition?
M. Ruth (2011)
Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials
M. Hlatky (2009)
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
M. Chapman (2010)
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.
D. Eurich (2005)
Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes—the ‘dead in bed’ syndrome revisited
G. Gill (2008)
Instruments to tailor care of people with type 2 diabetes.
A. Sigurdardottir (2009)
Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials.
Chirag P Bavishi (2017)
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of theEuropeanSocietyofCardiology(ESC)anddevelopedincollaboration
L. Rydén (2014)
Abstract 3735: Glucose Lowering Therapy in Post Myocardial Infarction Patients with Diabetes - is Insulin Safe? A report from the Euro Heart Survey on Diabetes and the Heart
M. Anselmino (2007)
Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study
Anna Kucharska-Newton (2009)
Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.
C. Vlachopoulos (2010)
Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure.
I. Gustafsson (2004)
Sudden coronary death in women.
W. Kannel (1998)
2018 ESC/EACTS Guidelines on myocardial revascularization.
Franz-Josef Neumann (2019)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
J. Green (2015)
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
S. Inzucchi (2014)
Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry.
S. Sedlis (2002)
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
P. Mitchell (2011)
Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.
M. Lenzen (2006)
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
P. Poole-wilson (2003)
Common Carotid Intima-Media Thickness Measurements in Cardiovascular Risk Prediction: A Meta-Analysis
H. Ruijter (2012)
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
R. Wing (2013)
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes
B. Rocca (2012)
Risk Prediction of Cardiovascular Disease in Type 2 Diabetes
J. Cederholm (2008)
Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.
C. Mogensen (1984)
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
P. Home (2007)
Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006.
M. Mehra (2006)
Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts
R. Santos-Oliveira (2011)
Group based training for self-management strategies in people with type 2 diabetes mellitus.
T. Deakin (2005)
The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease.
G. Hu (2005)
[ESC/EAS Guidelines for the management of dyslipidaemias].
Ž. Reiner (2011)
Low-dose aspirin for the prevention of atherothrombosis.
C. Patrono (2005)
Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study.
K. Malmberg (1997)
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
Trialists Antithrombotic (2002)
Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure
Lowdose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial
Y Saito (2017)
Trends in hypertension management in Type I diabetes across Europe, 1989/1990 – 1997/1999
S. Soedamah-Muthu (2003)
Risk estimation and the prevention of cardiovascular disease
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
K. Pantalone (2008)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).
B. Ibanez (2018)
Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015
Marissa B Nancy Marie Joseph S Amanuel Kalkidan Hassen Cri Reitsma Fullman Ng Salama Abajobir Abate Abbafati (2017)
Diuretics for heart failure
René R. Wenzel (1986)
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
Antithrombotic Trialists' (ATT) Collaboration (2009)
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
J. Bosch (2012)
Effects of beta-blockers on glucose and lipid metabolism
VA Fonseca (2010)
Independent risk factors for atrial fibrillation in a population-based cohort
EJ Benjamin (1994)
A trial of ESC Guidelines 3087i by gest on Jauary 27, 2015 D ow nladed fom darbepoetin alfa in type 2 diabetes and chronic kidney disease
MA Pfeffer (2009)
Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry.
S. Mulukutla (2008)
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
P. Gæde (2016)
Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes
S. Roberts (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
B. Neal (2017)
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
R. Scott (2009)
Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register
M. Eriksson (2011)
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
J. Perk (2012)
Gene Silencing of the Mitochondrial Adaptor p66Shc Suppresses Vascular Hyperglycemic Memory in Diabetes
F. Paneni (2012)
Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk
K. Khaw (2004)
Yusuf S; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind
S S Anand (2018)
Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data.
D. Capodanno (2011)
Coronary intervention for persistent occlusion after myocardial infarction.
J. Hochman (2006)
Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial
M. Macdonald (2015)
Increased glycemic variability and decrease of the postprandial glucose contribution to HbA1c in obese subjects across the glycemic continuum from normal glycemia to first time diagnosed diabetes.
M. Fysekidis (2014)
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
P. Kolkhof (2017)
Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension
Ali Gökhan Ozyıldız (2017)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
B. Scirica (2014)
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
G. Bardy (2005)
Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis
E. Bruckert (2011)
Diabetic and Nondiabetic Patients With Left Main and/or 3-Vessel Coronary Artery Disease: Comparison of Outcomes With Cardiac Surgery and Paclitaxel-Eluting Stents
V. Thourani (2011)
Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications.
G. Spectre (2011)
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
G. Bakris (2004)
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).
M. Brignole (2013)
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
A. Norhammar (2004)
The promise of cell-based therapies for diabetic complications: challenges and solutions.
Y. Jarajapu (2010)
Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure.
I. Johansson (2016)
Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus.
B. Gilbert (2018)
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial
C. Granger (2004)
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Patricia Campbell (2001)
The Role of Physical Activity in Type 2 Diabetes Prevention: Physiological and Practical Perspectives
J. Burr (2010)
Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake.
H. Bloomfield (2017)
Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials
S. Bangalore (2011)
Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial
J. Bolinder (2016)
Canagliflozin And Renal Outcomes In Type 2 Diabetes And Nephropathy
A. Gogia (2019)
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial
F. W. Mohr (2013)
Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
J. Ghali (2007)
Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study
F. Masoudi (2005)
Facilitated PCI in Patients with ST-Elevation Myocardial Infarction
B. Gersh (2009)
Renal and retinal effects of enalapril and losartan in type 1 diabetes.
M. Mauer (2009)
Rates of Progression in Diabetic Retinopathy During Different Time Periods
T. Wong (2009)
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
M. Pfeffer (1992)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
A. Catapano (2016)
Risk factors for heart failure in the elderly: a prospective community-based study.
Y. Chen (1999)
Motivational interviewing: a systematic review and meta-analysis.
S. Rubak (2005)
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
J. Liao (2008)
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
S. Yusuf (1991)
Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial
T. Haak (2016)
Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology.
F. Messerli (2006)
Major coronary risk factors and death from coronary heart disease: baseline and follow-up mortality data from the Second National Health and Nutrition Examination Survey (NHANES II).
G. Mensah (2005)
Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation
G. Nichols (2009)
Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
W. Elliott (2011)
Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis.
Liang Chen (2015)
Cardiovascular effects of bariatric surgery
A. Beamish (2016)
Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study.
P. Janssen (2009)
Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction
S. L. Kristensen (2016)
Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial
B. Lal (2012)
Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study
O. Hamdy (2017)
Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology
Bahira Shahim (2018)
Cardiovascular disease risk profiles.
K. M. Anderson (1991)
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration
S. Yusuf (1994)
5-yearoutcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study
B Lagerqvist (2006)
Arrhythmias: atrial fibrillation, ventricular arrhythmias, and sudden cardiac death
Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
X. Du (2009)
Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial.
L. Young (2009)
Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
A. Levin (2013)
Interventions for enhancing medication adherence.
R. Nieuwlaat (2014)
THE EFFECT OF NISOLDIPINE AS COMPARED WITH ENALAPRIL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES AND HYPERTENSION
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
S. Connolly (2009)
Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis
A. Steinsbekk (2012)
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
R. Holman (2010)
Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial.
A. Farmer (2009)
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
I. Tzoulaki (2009)
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
B. Zinman (2017)
Crossing the Quality Chasm: A New Health System for the 21st Century
A. Baker (2001)
Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.
L. Vaur (2003)
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.
M. Domanski (2003)
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
A. J. Camm (2010)
Trends in blood pressure control in patients with type 2 diabetes – Data from the Swedish National Diabetes Register (NDR)
P. Nilsson (2011)
Diets for Health: Goals and Guidelines.
Amy B. Locke (2018)
Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis.
R. Huxley (2009)
Renin inhibition in heart failure and diabetes: the real story
G. Rosano (2018)
Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes
C. Jarnert (2008)
Diabetes mellitus as a prothrombotic condition
P. Grant (2007)
This paper is referenced by
Glucose abnormalities detected by oral glucose tolerance test in patients with acute myocardial infarction: clinical significance, epidemiology, natural course and therapeutic concerns
Paweł Francuz (2017)
Temporal Trends and Familial Clustering of Ideal Cardiovascular Health in Parents and Offspring Over the Life Course: An Investigation Using The Framingham Heart Study.
James M Muchira (2020)
Two drugs are better than one to start T2DM therapy
Francesco Prattichizzo (2019)
Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review.
Laura van Iersel (2019)
[Acute coronary syndrome : Prevention].
Uwe Nixdorff (2019)
The simultaneous assessment of glycosylated hemoglobin, fasting plasma glucose and oral glucose tolerance test does not improve the detection of type 2 diabetes mellitus in Colombian adults
José Luis López-López (2018)
Metabolic risk markers and relative survival in patients with aortic stenosis requiring surgery
Anders Holmgren (2019)
Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source.
George Ntaios (2020)
Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions
Nadezda Apostolova (2020)
Impact of physical activity on hypoglycaemia in patients with diabetes
K. Zielińska (2018)
Medication Review by Community Pharmacists for Type 2 Diabetes Patients in Routine Care: Results of the DIATHEM-Study
Elisabeth Schindler (2020)
Diabetes mellitus and heart failure : registry based studies on risk factors, prognosis and impact of treatment
I. Johansson (2017)
Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
P. Men (2020)
Gender difference in the association of serum selenium with all-cause and cardiovascular mortality
J. Li (2019)
Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases
V. Panoulas (2020)
High fructose diet induces early mortality via autophagy factors accumulation in the rostral ventrolateral medulla as ameliorated by pioglitazone.
I. Lin (2019)
Epidemiology, risk factors, and opportunities for prevention of cardiovascular disease in individuals of South Asian ethnicity living in Europe.
Miguel Cainzos-Achirica (2019)
Management of Diabetes and/or Hyperglycemia in Acute Coronary Syndrome, Acute Stroke, and Acute Heart Failure
Miles Mark Fisher (2018)
Glucose‐lowering treatment in cardiovascular and peripheral artery disease
R. Suades (2018)
Efficacy and Safety of Ranolazine in Diabetic Patients: A Systematic Review and Meta-analysis
Xiaofang Zeng (2017)
2016 Consensus statement on prevention of atherosclerotic cardiovascular disease in the Hong Kong population.
Bernard Man Yung Cheung (2017)
Exercise Amaliorates Metabolic Disturbances and Oxidative Stress in Diabetic Cardiomyopathy: Possible Underlying Mechanisms.
Ayman M. Mahmoud (2017)
TEMPORARY REMOVAL: Paciente con alto riesgo cardiovascular y fibrilación auricular: papel del rivaroxabán
Vivencio Barrios (2020)
Role of aspirin in primary prevention of cardiovascular disease
Carlo Patrono (2019)
A prescription support-tool for chronic management of oral antithrombotic combinations in adults based on a systematic review of international guidelines
L. Zerah (2019)
Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.
F. Cosentino (2018)
Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy
S. Costantino (2019)
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
Kershaw V. Patel (2020)
Unconventional approaches to diabetes screening: Rejuvenation time for cardiovascular prevention strategies?
L. Liberale (2018)
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
Munemitsu Otagaki (2019)
Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial
L. Wang (2020)
COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ‐ Is there any scientific evidence for controversy?
A. Aleksova (2020)See more